New study proves e-ASPECTS could predict benefit of mechanical thrombectomy
Posted: 22 June 2017 | Sarah Wills (Drug Target Review) | No comments yet
A new study shows e-ASPECTS correlates with and is a predictor of outcome after mechanical thrombectomy. With mechanical thrombectomy gaining ground as a possible treatment for patients suffering from acute ischemic stroke, it is even more important to select those patients who can derive the most benefit.
e-ASPECTS has proved to be a patient selection tool which can assist, in line with international guidelines, in selecting the ones who are more likely to benefit from mechanical thrombectomy.
This study, the first with e-ASPECTS in patients who all underwent mechanical thrombectomy, confirmed substantial agreement of e-ASPECTS with manual ASPECTS done by expert readers. During the study, patients with low e-ASPECTS scores (0-5) showed a high probability of unfavourable outcome.
The results of this study have been published in the American Journal of Neuroradiology.
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
“This is the first clinical study to demonstrate e-ASPECTS correlation with treatment outcomes after mechanical thrombectomy. We are very excited that this study further demonstrates the significant value of e-ASPECTS in supporting and optimising life-saving treatment decisions,” says Dr. Michalis Papadakis, CEO of Brainomix .
Related topics
Imaging
Related conditions
Ischemic stroke
Related organisations
Brainomix
Related people
Dr Michalis Papadakis
